ClinicalTrials.gg
CompletedNCT03016013Updated Sep 26, 2024

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.

A Phase 3 interventional study of Placebo plus MTX and RC18 160 mg plus MTX in Moderate and Severe RheumatoId Arthritis, sponsored by RemeGen Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-09-26.

Sponsored by RemeGen Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
479
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 147 studies in Lymphoma, Follicular with a site in China — 75 open to participants now, 88 under way, 20 of them phase 3. Lymphoma, Follicular · China.

Enrollment
18th of 132
479 · median 93
Started
2017
with 9 others
Phase 3
28 of 147
13 open now
Registered
27th of 147
by date

Among the 147 studies in Lymphoma, Follicular with a site in China, this one is the 18th largest by enrollment of the 132 interventional ones that give a count, is one of 10 that started in 2017, is one of 28 in phase 3, and was the 27th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

75 of the 147 studies in Lymphoma, Follicular with a site in China are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Lymphoma, Follicular with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to initially access the safety and effectivity of RC18 combined with methotrexate (MTX) in comparison with the use of methotrexate alone in participants with moderate to severe Rheumatoid Arthritis (RA) who have an inadequate response to MTX therapy.

03

Conditions studied

  • Moderate and Severe RheumatoId Arthritis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of adult onset RA by a physician as defined by the 1987 and/or 2010 ACR criteria and ESR or C - reaction protein ( CRP ) is greater than the normal range;
  • Aged 18-65 years old;
  • Consent to use effective during the study period (women of childbearing age);
  • Patients with an inadequate response to existing therapies at least one anti-TNFs Infliximab (Remicade ) at least three times, adalimumab (Humira), at least four times, etanercept ( Enbrel) use at least 8 weeks, etanercept use at least 8 weeks.And Last medication time to randomization more than 12 weeks;
  • Voluntarily signed ;
  • Patients have been taking MTX for at least 12 weeks at the screening and maintaining dose stability ≥7.5mg/ weeks (or equivalent dose) 4 weeks before randomization;
  • Treatment with traditional oral disease-modifying antirheumatic drugs (DMARD) / agents other than MTX within 4 weeks or 12 weeks before the screening visit, depending on DMARD;
  • If subjects are receiving treatment of , must stabilize dose (dose of prednisone) at least equal to or less than 10mg/day for 4 weeks (before randomization);
  • If subjects are receiving treatment of NSAIDs,must stabilize dose (dose of prednisone) at least 4 weeks (before randomization);
  • When the patient's condition to achieve moderate to severe active RA at the screening, defined as at least 6/68 tenderness joints and at least 6/66 swollen joints.

Exclusion criteria

Exclusion Criteria:

  • Exclusion criteria associated with rheumatoid disease:

    1. The subjects with any other inflammatory arthritis (such as juvenile chronic arthritis, regional enteritis (Krohn S disease), ulcerative colitis, gout, active vasculitis, psoriatic arthritis or ankylosing spondylitis);
    2. The subjects with secondary, non inflammatory arthritis (such as osteoarthritis or fibromyalgia), and researchers think the symptoms of arthritis can interfere with judgment and evaluation study on therapeutic effects of drugs.But secondary Sjogren syndrome (SjÖgren), thyroiditis without exclusion;
    3. The subjects had a history of prosthetic joint infection, whenever the infection occurred, and the artificial joint is still in the body;
    4. The subjects due to RA and/or shoulder hand syndrome IV grade received more than 3 times the arthroplasty;
    5. The subjects' Types of X-ray phases reach IV phase.
  • The subjects can not accept the prohibited drugs listed in the following table:

    1. Use of analgesics (acetaminophen / paracetamol) within 24 hours before baseline assessment;
    2. dosage regimen of nonsteroidal anti-inflammatory analgesic NSAIDs/COX-2 inhibitors (except acetaminophen) have occurred any change within 14 days before baseline assessment;
    3. The dosage of oral have occurred any change within 28 days before baseline assessment;
    4. Intramuscular injection/intravenous injection/intra-articular injection of glucocorticoid has used within 28 days before baseline assessment;
    5. Intra-articular injection of hyaluronic acid has used within 28 days before baseline assessment;
    6. Tripterygium wilfordii or other traditional Chinese medicine for treating RA has used within 28 days before baseline assessment.
  • The researchers confirmed that the subjects had current or recent severe, progressive and or not controlled heart, lung, liver, kidney and other important organs and blood, endocrine system lesions and history; Abnormal laboratory parameters need to be excluded, including but not limited to:

    1. Cr >135μmol/L or 5 times the upper limit of laboratory reference value;
    2. WBCs\<3x 109/L;
    3. neutrophile granulocyte \<1.5×109/L;
    4. \<85g/L;
    5. count\<80x 109/L;
    6. total > 1.5 times the upper limit of laboratory reference value;
    7. > 2 times the upper limit of laboratory reference value;
    8. ALT > 2 times the upper limit of laboratory reference value;
    9. alkaline phosphatase > 2 times the upper limit of laboratory reference value.
  • -surface antigen positive patients are not allowed to be selected, but only anti HBC single positive is added to do HBV-DNA quantitative detection, if the HBV-DNA quantity is negative can not be regarded as the exclusion.
  • The anti- of patients show positive.
  • Infection with herpes zoster or virus at the screening.
  • The subjects at high risk of infection ;such as leg ulcers, indwelling catheter, persistent or recurrent chest infection, completely bedridden or sedentary wheelchair subjects.
  • There is a history of chronic infection, severe or life-threatening infections (including shingles) within the last 6 months, or any signs or symptoms during the screening period that may indicate an infection (e.g. fever, cough).
  • the subjects currently or recently (30 days before screening) suffers from severe viral, bacterial, fungal, or parasitic infections.
  • pregnant, lactating women and men or women who have birth plans in the past 6 months.
  • Have a history of allergic reaction to contrast agent for parenteral administration and human biological medicines.
  • The subjects receive /attenuated vaccine within the first 8 weeks before screening or those who are known to receive live vaccine/attenuated vaccine during the trial.
  • Have participated in any clinical trial in the first 28 days of the initial screening or 5 times half-life period of the study compound (taking the time for the elderly).
  • Patients with using of biological agents for the treatment of DMARDs within three months.
  • Active TB at screening.Exception for patients with PPD≥15mm.But Patients with anti tuberculosis treatment for 3 years without relapse are allowed to participate in the trial.
  • Malignant tumor patients :the patients who suffering from malignant tumor has been removed and no recurrence or who with cervical carcinoma in situ have evidence of disease and with basal cell or squamous cell carcinoma had been completely removed and at least 3 years without recurrence can participate in.
  • The patients with a history of lymphoproliferative disease (including lymphoma or signs and symptoms of lymphoproliferative disease at any time).
  • the patients have no effective in using of tumor necrosis factor inhibitors;
  • there was a history of long-term alcohol abuse, intravenous drug abuse or other illicit drug abuse within 6 months.
  • Planning to have surgery for RA or other significant surgery during the period of the study.
  • patients experienced any of the following events within 12 weeks before screening: myocardial infarction, unstable ischemic heart disease, stroke, or class IV heart failure.
  • Patients received interferon treatment (such as interferon alpha, intron alpha, peg-intron, double talon, intergen, Pegasys etc.) within 4 weeks before screening,or are expected to test period will need to accept interferon therapy.
  • The combined use of agents associated with organ. transplantation is not allowed during the study period.
  • Immunosuppressive agents associated with organ transplantation should not be allowed during the study period.
  • Investigator considers candidates not appropriating for the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
479 participants (actual)

Study arms

  • Placebo comparator
    Placebo plus MTX

    Patients received placebo SC plus MTX weekly administered subcutaneously for 24 times.All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose. All subjects received RC-18 treatment once a week from week 24 to week 48.

    Biological: Placebo plus MTX

  • Experimental
    Experimental: RC18 160 mg+MTX

    Patients received the test group RC18 160mg plus MTX weekly administered subcutaneously for 24 times. All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.

    Biological: RC18 160 mg plus MTX

Interventions

  • BiologicalPlacebo plus MTX

    The trial was divided into two groups: (1) placebo + MTX; (2) telitacicept 160 mg + MTX. MTX was used as the basic treatment, the dose of MTX was stable during the trial, and could not be adjusted. Telitacicept or placebo was administered once a week for the first 24 weeks. Beginning at week 24, subjects in the placebo group will enter the RC-18 treatment group. All subjects received RC-18 treatment once a week from week 24 to week 48.

    Also known as: MTX=Methotrexate

  • BiologicalRC18 160 mg plus MTX

    Drug page: Telitacicept

    The trial was divided into two groups: (1) placebo + MTX; (2) telitacicept 160 mg + MTX. MTX was used as the basic treatment, the dose of MTX was stable during the trial, and could not be adjusted. Telitacicept or placebo was administered once a week for the first 24 weeks. Beginning at week 24, subjects in the placebo group will enter the RC-18 treatment group. All subjects received RC-18 treatment once a week from week 24 to week 48.

    Also known as: RC18, MTX=Methotrexate

06

What researchers measure

Primary outcomes

  1. The proportion of patients in each group reached ACR20 at week 24

    ACR20 response: Patients with tenderness and swollen joint counts and 20% improvement,At least 3 20% improvement in the following 5:a.Health Assessment Questionnaire;b.Subjects assessed pain VAS score;c.Assess the overall situation of the disease subject VAS score;d.Researchers assessed the overall situation of the disease in the VAS score;e.Acute phase reactants(ESR or CRP).

    Time frame: Week 24(Visit 9)

Secondary outcomes

  1. Percentage of Participants Achieving American College of Rheumatology ACR50 and ACR70 Responses at week 24.

    Time frame: Week 24

  2. Percentage of Participants Achieving Low Disease Activity and clinical remission. (DAS28 ≤3.20 and DAS28 < 2.6).

    Disease activity score based on 28 painful joint counts, 28 swollen joint counts, erythrocyte sedimentation rate (ESR) mm/hr, and general health (GH) using a visual analog scale (VAS); VAS range: 0 (very well) to 100 (extremely bad). DAS28 score calculated as 0.56 √ (28 painful joint count) + 0.28 √ (28 swollen joint count) + 0.70 (ln ESR mm/hr) + 0.014 GH; range 0 to 10. DAS28 score \>5.10=higher disease activity; \<3.20=low disease activity; \<2.60=clinical remission.

    Time frame: Week 24

  3. Percentage of Participants Achieving American College of Rheumatology ACR50 and ACR70 Responses at week 12 or week 24.

    Time frame: Week 12 and Week 24

  4. Sharp Score Relative Change from Baseline at Week 24

    Time frame: Week 24

  5. Percentage of Participants With American College of Rheumatology 20% ,50% and 70% (ACR20, ACR50 and ACR70) Response

    Time frame: Week 4, Week 8, Week 12, Week 28, Week 32, Week 40, Week48

  6. Change From Baseline in Joint Space Narrowing and Erosions at week 24 and week 48.

    Erosion score (a component of the modified TSS) is a measure of change in joint health. Erosion score range is from 0 (no erosion) to 280 (high erosion).And Joint space narrowing score (a component of the modified TSS) also is a measure of change in joint health. Joint space narrowing score range is 0 (no narrowing) to 168 (high narrowing).

    Time frame: Week 24,Week48

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, Beijing 100730, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Nov 2022, 67 months.

Of 45 industry-sponsored phase 3 interventional studies under Lymphoma, Follicular, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 86. This study's 67 months is above that.

Counting every sponsor, half of 80 studies reached it within 63 months; a quarter within 36 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2017
First posted
Jan 10, 2017
StartActual
Mar 29, 2017
Primary completionActual
Nov 19, 2022
CompletionActual
Dec 29, 2022
Last update
Sep 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03016013
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Jan 10, 2017
Start date
Mar 29, 2017
Primary completion
Nov 19, 2022
Completion
Dec 29, 2022
Last update
Sep 26, 2024

Study contacts

Fengchun Zhang
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telitacicept

Start the discussion